Search results for "Product characteristics"

showing 10 items of 12 documents

The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs.

2013

The Biopharmaceutics Classification System (BCS) defines the solubility characteristics of an active pharmaceutical substance based on its dose-solubility ratio: for highly soluble drugs this ratio is less than 250 mL over a defined pH range. Prior to the revision of the European Medicines Agency (EMA, formerly EMEA) guideline in 2010, the "dose" in this ratio was consistently defined by the US FDA, the EMA, and the WHO biowaiver guidelines as the highest dosage strength. However, in the revised EMA guideline, the dose is defined as the highest single dose administered according to the Summary of Product Characteristics. The new EMA criterion for highly soluble may be closer to the actual c…

Active ingredientbusiness.industryMetoclopramidePharmaceutical ScienceGuidelineBioequivalencePharmacologyBiopharmaceutics Classification SystemBiopharmaceuticsSolubilityVerapamilPh rangeMedicineHumansRegulatory scienceDosingSummary of Product CharacteristicsbusinessJournal of pharmaceutical sciences
researchProduct

Italian Health Care Workers’ Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Infection and Prevention

2020

Objective: To assess healthcare workers&rsquo

AdultMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyHPVknowledgegenetic structuresHealth PersonnelHealth Toxicology and MutagenesisUterine Cervical Neoplasmslcsh:MedicineScientific literatureimmunizationSettore MED/42 - Igiene Generale E ApplicataArticle03 medical and health sciences0302 clinical medicinepreventionAttitude Awareness Healthcare workers HPV Immunization Knowledge Practice Prevention Sexually transmitted infection Adult Cross-Sectional Studies Female Italy Middle Aged Papillomavirus Vaccines Papillomavirus Infections Uterine Cervical NeoplasmsSurveys and QuestionnairesvaccineIntervention (counseling)Health caremedicineHumansAttitude; Awareness; Healthcare workers; HPV; Immunization; Knowledge; Practice; Prevention; Sexually transmitted infection; VaccineawarenessPapillomavirus Vaccinessexually transmitted infection030212 general & internal medicineHuman papillomavirusbusiness.industryhealthcare workersPapillomavirus Infectionslcsh:RPublic Health Environmental and Occupational HealthMiddle AgedProduct characteristicspracticeCross-Sectional StudiesItaly030220 oncology & carcinogenesisFamily medicineattitudeMulticenter surveyPropensity score matchingFemalebusinessInternational Journal of Environmental Research and Public Health
researchProduct

THE SURVIVAL OF DIFFERENTIATED PRODUCTS: AN APPLICATION TO THE UK AUTOMOBILE MARKET, 1971-2002*

2009

We investigate how competition affected the survival of products in the UK automobile market between 1971 and 2002. We find, after using a host of controls to account for product characteristics and changes in market structure, that (i) within and between firm spatial competition significantly reduces the life of a model, (ii) initial product differentiation and variant proliferation obviate competition, and (iii) product innovation significantly extends model survival.

Competition (economics)Economics and EconometricsMarket structureProduct innovationAutomobile marketEconomicsProduct differentiationProduct characteristicsIndustrial organizationThe Manchester School
researchProduct

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

2006

Aims To compare information on drug–drug interactions (DDIs) reported on two standard drug-related information sources (Summary of Product Characteristics and Drugdex system by Micromedex), by assessing the prevalence and predictors of potential DDI with proton pump inhibitors (PPIs) in general practice. Methods From the ‘Caserta-1’ Local Health-Service database, 156 general practitioners (GPs) were recruited. From more than 180 000 individuals registered on their lists, we selected patients receiving co-prescription of PPI and medications at interaction risk, according to the Italian Summary of Product Characteristics (SPC) of PPI and Drugdex information, during the year 2003. Thereafter, …

DrugAdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectPharmacology toxicologyToxicologyDrugdexDrug PrescriptionsInternal medicineEpidemiologymedicineHumansPharmacology (medical)Drug InteractionsSummary of Product CharacteristicsRisk factorMedical prescriptiondrug information sourcesSummary of Product Characteristicsmedia_commonAgedgeneral practicePharmacologyAged 80 and overObserver VariationDrug pairbusiness.industryPharmacoepidemiologydrug information sources Drugdex drug–drug interaction general practice proton pump inhibitors Summary of Product CharacteristicsRegression analysisProton Pump InhibitorsDrug interactionMiddle Ageddrug information sources; Drugdex; drug-drug interaction; general practice; proton pump inhibitors; Summary of Product CharacteristicsSpontaneous reportingFamily medicineDrug Information ServicesInformation sourceFemalebusinessFamily Practicedrug-drug interactionBritish journal of clinical pharmacology
researchProduct

Calculating Hedonic Price Indices with Unobserved Product Attributes: An Application to the UK Car Market

2006

We show that hedonic price indices that omit model-specific unobservable product attributes are subject to considerable bias. We utilize a complete panel of new car versions marketed in the UK over 1971–98 which incorporates over 100 observable product characteristics, sales weighting to capture the distribution of purchases across models, and model-specific fixed effects to account for unobservable characteristics. We find that quality-adjusted prices obtained from hedonic regressions that do not account for unobservable characteristics exhibit a severe downward bias. We also show that quality-adjusted prices exhibit distinct sub-market differences having increased in ‘mass production’ seg…

Economics and Econometricsbusiness.industryHedonic indexDistribution (economics)Product characteristicsUnobservableWeightingMicroeconomicsPrice indexEconomicsEconometricsProduction (economics)Product (category theory)businessEconomica
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Corporate entrepreneurship and human resource management: theoretical background and a case study

2011

Purpose: This article aims to review varying concepts of entrepreneurship and different contributions to human resource practices, establishing a theoretical framework that allows for the analysis of the firm Montalt-Valencia (Spain), a Ford-Spain car dealer, and leader in its sector. Design/methodology/approach: The paper, according to the literature, establishes a theoretical framework on entrepreneurship and human resource management through which one can observe and research the Montalt-Valencia case study. The case study is confirmatory, from the theoretical background, and at the same time inductive from the observation of its non-expected details and deeds. Findings: The firm Montalt…

Organizational Behavior and Human Resource ManagementEntrepreneurshipProcess managementbusiness.industryProcess (engineering)Strategy and ManagementEntrepreneurialismProduct characteristicsEntrepreneursSpainManagement of Technology and InnovationHuman resource managementEconomicsORGANIZACION DE EMPRESASHuman resource managementOperations managementHuman resourcesbusiness
researchProduct

French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs

2010

The prescription information (summary of product characteristics, SPC) is compiled by the pharmaceutical industry as required by the national regulatory authorities. They vary in their content about the properties of drugs and about the usefulness of therapeutic drug monitoring (TDM) in the blood of patients. Based on a previous study carried out in Germany, the degree of agreement of French SPC for 59 psychotropic drugs with the existing medico-scientific evidence in the area of TDM was examined using a recently developed instrument. A summary score of SPC content (SPCC) related to TDM (SPCC TDM ) has been calculated and compared with the level of recommendation of TDM of the AGNP-TDM expe…

PharmacologyDrugmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedia_common.quotation_subjectProduct characteristicsNeuropsychopharmacologyMoodTherapeutic drug monitoringmedicinePharmacology (medical)Summary of Product CharacteristicsMedical prescriptionPsychiatrybusinessmedia_commonPharmaceutical industryFundamental & Clinical Pharmacology
researchProduct

Vitamins in wine: Which, what for, and how much?

2021

Vitamins are essential compounds to yeasts, and notably in winemaking contexts. Vitamins are involved in numerous yeast metabolic pathways, including those of amino acids, fatty acids, and alcohols, which suggests their notable implication in fermentation courses, as well as in the development of aromatic compounds in wines. Although they are major components in the course of those microbial processes, their significance and impact have not been extensively studied in the context of winemaking and wine products, as most of the studies focusing on the subject in the past decades have relied on relatively insensitive and imprecise analytical methods. Therefore, this review provides an extensi…

WineComplex matrix010401 analytical chemistryfood and beveragesWineContext (language use)Saccharomyces cerevisiaeVitamins04 agricultural and veterinary sciencesProduct characteristicsBiology040401 food science01 natural sciencesYeast0104 chemical sciences0404 agricultural biotechnologyFermentationVitisFermentationFood scienceFood ScienceWinemakingComprehensive Reviews in Food Science and Food Safety
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct